QPPV.COM KNOWLEDGE ASSESSMENT

Basiliximab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Basiliximab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which aggregate-analysis practice would risk masking an important basiliximab safety pattern?

Separating first-exposure from re-exposure hypersensitivity cases Preserving transplant timing and dose sequence Pooling all hypersensitivity reactions without retaining prior-exposure status Reviewing serious infection in relation to maintenance immunosuppression

Question 2 of 10 A kidney-transplant recipient develops CMV infection several months after basiliximab induction. Which causality approach is most appropriate?

Attribute the infection automatically to basiliximab because it is immunosuppressive Exclude any relationship because basiliximab is given only twice Assess maintenance immunosuppression, rejection treatment, prophylaxis, graft function and host factors before attributing causality Attribute it primarily to the donor kidney without reviewing treatment history

Question 3 of 10 Which additional information is particularly important in a paediatric basiliximab case?

Adult body mass only Age, weight, dose, transplant chronology and whether the applicable paediatric dosing criteria were followed Only the child's vaccination history Only the donor's age

Question 4 of 10 Which clinical use best reflects the role of basiliximab described in the article?

Continuous monotherapy for lifelong prevention of all transplant complications Short-course induction immunosuppression around de-novo kidney transplantation Treatment of established bacterial infection after transplantation Replacement of all maintenance immunosuppressive medicines

Question 5 of 10 A post-transplant lymphoproliferative disorder is reported after basiliximab induction. Which information is most important for contextual assessment?

Only the exact time of the basiliximab infusion Cumulative immunosuppression, EBV status where available, rejection treatment, pathology and latency Only whether the patient experienced rash during infusion The basiliximab dose without information about other medicines

Question 6 of 10 A report concerns a defect in a co-packed water-for-injection ampoule, but it is unclear whether the affected material was used. How should the issue be handled?

Treat it automatically as an intrinsic pharmacological adverse reaction Discard it because no adverse event is confirmed Document it as a product-quality or administration issue, establish whether exposure occurred, and record any clinical consequence Combine it with all hypersensitivity cases without distinguishing the defect

Question 7 of 10 Which set of information is most useful when evaluating an apparent lack of basiliximab efficacy?

Only the presence of a post-transplant creatinine increase Biopsy or clinical rejection evidence, immunological risk, adherence, concomitant regimen and relevant drug concentrations Only the basiliximab batch number Only whether the patient experienced an infusion reaction

Question 8 of 10 A patient develops fever, hypoxia and hypotension during or shortly after basiliximab administration. Which approach best reflects the article's recommendation?

Classify the event automatically as anaphylaxis because it occurred during infusion Classify it automatically as cytokine-release syndrome because basiliximab is a monoclonal antibody Differentiate among hypersensitivity, cytokine-release-type reaction, sepsis and fluid overload using timing and clinical findings Exclude basiliximab because cytokine-release-type reactions are impossible with this mechanism

Question 9 of 10 Which attribution principle is most appropriate for cytopenia, nephrotoxicity or metabolic abnormalities after transplantation?

Assume basiliximab is the cause because it was part of the induction regimen Assume surgery is always the cause and do not review medicines Evaluate basiliximab, maintenance immunosuppressants, surgery, graft dysfunction and other plausible causes as a combined context Attribute every event to rejection regardless of clinical evidence

Question 10 of 10 Which feature most clearly distinguishes basiliximab-specific acute risk from transplant-system background risk?

A severe reaction beginning shortly after administration is more product-specific than sepsis months later during ongoing maintenance immunosuppression All later events are unrelated to basiliximab because exposure was short All transplant complications are caused by basiliximab because it is immunosuppressive Timing has no relevance in biological-product causality assessment

Basiliximab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Cookie Settings